Article Text

PDF

GW23-e1340
COMPARISON OF ASPIRIN COMBINED NAOXINTONG VERSUS ADJUSTED-DOSE WARFARIN IN ELDERLY PATIENTS WITH HIGH-RISK NON-VALVULAR ATRIAL FIBRILLATION AND GENETIC VARIANTS OF VKORC1
  1. Chen Hui,
  2. Wu Xiaoying,
  3. Chen Hui
  1. Fujian Provincial Cardiovascular Disease Institute

    Abstract

    Objectives Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin. But patients especially in Chinese population with genetic variants of vitamin K epoxide reductase (VKORC1), who received warfarin had more than as many haemorrhages than those who received aspirin.

    Objective To compare between aspirin combined BNC versus adjusted-dose warfarin in more than 65 years of age patients with high-risk non-valvular atrial fibrillation (NVAF) and genetic variants of VKORC1.

    Methods 151 patients with NVAF and the allelic mutation of VKORC1 gene-1639G>A and a CHADS2 score of 2 and above were randomly divided into two groups. One group was warfarin maintenance dosing adjustment nomogram for INR goal of 2–3, the other group was aspirin (100 mg/d) combined BNC (1.6 g thrice daily) as antithrombotic drug. All drugs were taken at least 1 year and clinical events (ischaemic stroke, haemorrhage, death) were followed up.

    Results Baseline clinical data were similar in both groups. Ischaemic stroke and the all-cause death did not significant difference between two groups. The serious bleeding rate of the combined group was less than that of the adjusted-dose warfarin group (0% vs 7.9%, OR=0.921, 95% CI 0.862 to 0.984, p=0.028).

    Conclusions Aspirin combined BNC and the adjusted-dose warfarin was equally effective in elderly patients with NVAF for prevention of ischaemic stroke. The combination therapy could reduce the risk of the antithrombotic drug therapy-associated bleeding.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.